Rectal Cancer Clinical Trial
Official title:
Transanal Minimally Invasive TME (TaTME) Versus Open Intersphincteric Resection and Total Mesorectal Excision of Stage II/III Ultralow Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy.
The two surgical options for lower 1/3 rectal cancer is APR and sphincter sparing procedures. Intersphincteric resection is procedure to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent colostomy,improves the quality of life with better genitourinary function. Neoadjuvant chemo-radiotherapy is routine for T3 cases.
During the period between April 2013 and July 2019, a non-randomized controlled study was
performed at two tertiary centers; Oncology Centre of Mansoura University and Policlinico
Umberto Primo surgery department of SAPIENZA university of Rome after referral from the
clinical oncology and nuclear medicine department. After diagnosis of ultralow rectal cancer,
a written informed consent was obtained from patients after full explanation of the
procedure, the likely outcome and the potential complications that may occur. Digital rectal
examination was conducted to assess the distance of lower tumor margin from the anal verge
and the anal tone. Anesthetic fitness and tumour markers (CEA) were assessed. Pelvis MRI
and/or endorectal ultrasound (EUS), abdomen and chest CT scan and colonoscopy with biopsy
were done for all cases. Re-evaluation after neoadjuvant chemo-radiotherapy by MRI and EUS.
Inclusion criteria included a very low rectal cancer below 5 cm from the anal verge with
normally continent and tumor-free external anal sphincter. Neoadjuvant treatment was given to
all patients with T3 or node positive tumors. Exclusion criteria were T4, metastatic tumors
and fecal incontinence. Fifty patients were excluded from the study (Fig.1). One hundred and
ten patients with ultralow rectal adenocarcinoma, with matched age and sex (table 1), were
non-randomly classified into two equal groups: the control group included 55 patents that
underwent sphincter sparing by open ISR with TME (O-ISR Group) and the 2nd group included 55
patents that underwent Transanal minimally invasive ISR with TME (TAMIS Group).
Surgical technique:
In open ISR, the inferior mesenteric vessels were highly ligated. After full mobilization of
the left colon and splenic flexure was done, the plane for TME was followed down in the
pelvis superficial to the hypogastric fascia as low as possible to enter into the posterior
intersphincteric plane. A non-endoscopic perineal phase was then initiated using an anal
lone-star retractor to expose the anal canal. Both the mucosa and the muscular layer were
incised 1cm below the tumor margin to transect the internal anal sphincter (IAS) and then
closed by purse string sutures. The dissection continued between IAS and the external anal
sphincter (EAS) starting posteriorly then laterally, where EAS is easier to identify, then
anteriorly where the plane presented more adhesions with the urethra in male or vagina in
female till reaching the abdominal dissection. Proximal division of the specimen started just
below the site of inferior mesenteric vessels ligation and continued till division of the
marginal artery at the site of the required anastomosis. The Specimen extraction and division
was done extra-anal. A defunctioning ileostomy was done in all cases.
In TAMIS-TME, using a lone star retractor, the 1st step was to divide and close the anal
canal by purse-string suturing to enter the intersphincteric plane. Using TEo platform (Karl
Storz, Tuttilingen, Germany) (fig. 2) with a 4 cm size operating proctoscope diameter,
Transanal endoscopic dissection was initiated and continued in the intersphincteric plane
starting posteriorly then laterally. Partial or high ISR started at the dentate line to
remove the upper half of IAS for ultralow tumors at 3 to 4.5 from anal verge. Total or low
ISR started 1 cm below the dentate line, removing the whole of IAS for tumours below 3 cm
from the anal verge. The endoscopic dissection continued in the same sequence as the control
group along the levator ani. Then continue posteriorly till reaching as much as possible,
then dissection continued laterally and anteriorly to reach the peritoneal reflection. Then,
the laparoscopic phase was initiated to ligate the inferior mesenteric vessels and mobilize
the splenic flexure and left colon. The peritoneal reflections were then divided to connect
to the transanal part. The specimen was then extracted transanally and the Colo-anal
anastomosis was done in two layers. A defunctioning ileostomy was done in all cases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |